BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 37569864)

  • 1. Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.
    Fiorentino V; Pizzimenti C; Franchina M; Rossi ED; Tralongo P; Carlino A; Larocca LM; Martini M; Fadda G; Pierconti F
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.
    Pierconti F; Martini M; Cenci T; Fiorentino V; Gianfrancesco LD; Ragonese M; Bientinesi R; Rossi E; Larocca LM; Racioppi M; Bassi PF
    Urol Oncol; 2022 Mar; 40(3):108.e19-108.e25. PubMed ID: 34903453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
    Pierconti F; Martini M; Fiorentino V; Cenci T; Capodimonti S; Straccia P; Sacco E; Pugliese D; Cindolo L; Larocca LM; Bassi PF
    Urol Oncol; 2021 Feb; 39(2):131.e17-131.e21. PubMed ID: 32773233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group.
    Pierconti F; Rossi ED; Cenci T; Carlino A; Fiorentino V; Totaro A; Sacco E; Palermo G; Iacovelli R; Larocca LM; Bassi PF; Martini M
    Cancer Cytopathol; 2023 Mar; 131(3):158-164. PubMed ID: 36262084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; D'Elia C; Mian C; Schwienbacher C; Hanspeter E; Pycha A; Kafka M; Degener S; Danuser H; Roth S; Pycha A
    Cancer Cytopathol; 2019 Jul; 127(7):465-469. PubMed ID: 31154670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial.
    Territo A; Gallioli A; Diana P; Boissier R; Fontana M; Gaya JM; Sanguedolce F; Calderón J; Piana A; Fontanet S; Algaba F; Palou J; Breda A
    J Urol; 2022 Sep; 208(3):570-579. PubMed ID: 35549312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation study of the Paris system for reporting urinary (TPS) categories.
    Pierconti F; Martini M; Cenci T; Fiorentino V; Sacco E; Bientinesi R; Pugliese D; Iacovelli R; Schinzari G; Larocca LM; Bassi PF
    J Clin Pathol; 2021 Feb; 74(2):102-105. PubMed ID: 32527754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples.
    Pierconti F; Martini M; Fiorentino V; Cenci T; Racioppi M; Foschi N; Di Gianfrancesco L; Sacco E; Rossi E; Larocca LM; Bassi PF
    Hum Pathol; 2021 Dec; 118():42-48. PubMed ID: 34582934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of the Urine Methylation Test (Bladder EpiCheck
    Peña KB; Riu F; Hernandez A; Guilarte C; Badia J; Parada D
    J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
    Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of semaphorin 3A in patients with urothelial cancer.
    Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
    Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of Xpert® BC Detection, Bladder Epicheck®, Urovysion® FISH and cytology in the detection of upper urinary tract urothelial carcinoma.
    Pycha S; Trenti E; Mian C; Schwienbacher C; Hanspeter E; Palermo M; Pycha A; Danuser H; D'Elia C
    World J Urol; 2023 May; 41(5):1323-1328. PubMed ID: 36929411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voided urine versus bladder washing cytology for detection of urothelial carcinoma: which is better?
    Keller AK; Jensen JB
    Scand J Urol; 2017 Aug; 51(4):290-292. PubMed ID: 28398114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of fluorescence in situ hybridization for diagnosis and surveillance of bladder urothelial carcinoma.
    Huang JW; Mu JG; Li YW; Gan XG; Song LJ; Gu BJ; Fu Q; Xu YM; An RH
    Urol J; 2014 Nov; 11(6):1974-9. PubMed ID: 25433477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck® as a diagnostic tool in upper urinary tract tumor.
    Palermo M; D'Elia C; Trenti E; Comploj E; Mian C; Schwienbacher C; Heidegger I; Clauser S; Pycha A; Vjaters E
    Minerva Urol Nephrol; 2024 Apr; 76(2):195-202. PubMed ID: 38498297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.